In an in vivo study, rhythmical treatment with vincristine combined with Endo (Met NVB+Endo) gave better results than a maximum tolerated dose of vincristine combined with Endo (MTD NVB+Endo) in terms of anti-tumor responses, reduction of CD31, VEGF, HIF-1α and CEPS expression, as well as reduction of toxic side effects and induction of apoptosis. The gene discussed is VEGFA; the disease is neoplasm.